



PTO/SB/08A (08-03)

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/727,100
		Filing Date	December 2, 2003
		First Named Inventor	Erlander, Mark G.
		Art Unit	1636
		Examiner Name	Not yet assigned Schlapkohl
Sheet 1	of 2	Attorney Docket Number	022041-001410US


U.S. PATENT DOCUMENTS+						
Examiner Initials*	Cite No. ¹	Document Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (# known)			
	AA	US-				
	AB	US-				
	AC	US-				
	AD	US-				
	AE	US-				
	AF	US-				
	AG	US-				
	AH	US-				
	AI	US-				
	AJ	US-				
	AK	US-				
	AL	US-				
	AM	US-				
	AN	US-				
	AO	US-				
	AP	US-				
	AQ	US-				
	AR	US-				
	AS	US-				
	AT	US-				

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³	Number ⁴	Kind Code* (if known)				
WS	AU	PCT	WO02/10332 0	A2	12/27/2002	Dal, et al.		<input type="checkbox"/>
	AV							<input type="checkbox"/>
	AW							<input type="checkbox"/>
	AX							<input type="checkbox"/>
	AY							<input type="checkbox"/>
	AZ							<input type="checkbox"/>
	BA							<input type="checkbox"/>
	BB							<input type="checkbox"/>

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Unsaved Document



PTO/SB/08B (08-03)


Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/727,100
		Filing Date	December 2, 2003
		First Named Inventor	Erlander, Mark G.
		Art Unit	1636
		Examiner Name	Not yet assigned Schlapkohl
Sheet 2 of 2	Attorney Docket Number	022041-001410US	

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
WS	BC	DAIDONE, M.G., et al. "Biomarkers and outcome after tamoxifen treatment in node-positive breast cancers from elderly women", <i>British Journal of Cancer</i> (2000) 82(2):270-277	
	BD	VAN DER FLIER, Silvia, et al. "Bcar 1/p130Cas Protein and Primary Breast Cancer: Prognosis and Response to Tamoxifen Treatment", <i>Journal of the National Cancer Institute</i> , (2000) Vol. 82(2):120-127	
	BE	LUO, L-Y, et al. "Higher expression of human kallikrein 10 in breast cancer tissue predicts tamoxifen resistance", <i>British Journal of Cancer</i> (2002) 86:1790-1796	
	BF	ELLIS, Matthew J., et al. "Neoadjuvant comparisons of aromatase inhibitors and tamoxifen: pretreatment determinants of response and on-treatment effect", <i>Journal of Steroid Biochemistry & Molecular Biology</i> (2003) 88:301-307	
	BG	HILSENBECK, Susan G., et al. "Statistical Analysis of Array Expression Data as Applied to the Problem of Tamoxifen Resistance", <i>Journal of the National Cancer Institute</i> (1999) 91(5):453-459	
	BH	VANT VEER, Laura, et al. "Gene expression profiling predicts clinical outcome of breast cancer", <i>Nature</i> (2002) 415:530-536	
	BI	MA, Xiao-Jun, et al. "A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen", <i>Cancer Cell</i> (2004) 5:607-615	
	BJ	BECKER, Michael, et al. "Distinct gene expression patterns in a tamoxifen-sensitive human mammary carcinoma xenograft and its tamoxifen-resistant subline MaCa 3386/TAM", <i>Molecular Cancer Therapeutics</i> (2005) 4(1):151-168	
WS	BK	RAMASWAMY, Sridhar, et al., "A molecular signature of metastasis in primary solid tumors", <i>nature genetics</i> (2003) 33:49-54	
	BL		
	BM		

Examiner Signature	/Walter Schlapkohl/	Date Considered	1/31/2007
--------------------	---------------------	-----------------	-----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.



PTO/SB/08B (08-03)

Substituted Form 1448B (08-03) INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/727,100
				Filing Date	December 2, 2003
				First Named Inventor	Erlander, Mark G.
				Art Unit	1634 1636
				Examiner Name	J.S. Sutton Schlapkohl
Sheet 1 of 1	Attorney Docket Number 022041-001410US				

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
WS	BC	BARDOU, V.J., et al. "Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases", <i>J. Clin Oncol</i> (2003) 21:1973-9	
	BD	HUANG, E. et al. "Gene expression predictors of breast cancer outcomes", <i>Lancet</i> (2003) 361:1590-6	
	BE	SØRLIE, T., et al. "Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications", <i>Proc Natl Acad Sci USA</i> (2001) 98:10869-74	
	BF	SØRLIE, T. et al. "Repeated observation of breast tumor subtypes in independent gene expression data sets", <i>Proc Natl Acad Sci USA</i> (2003) 100:8418-23	
	BG	SOTIRIOU, C., et al. "Breast cancer classification and prognosis based on gene expression profiles from a population-based study", <i>Proc Natl Acad Sci USA</i> (2003) 100:10393-8	
	BH	van de VIJVER, M.J., et al. "A gene-expression signature as a predictor of survival in breast cancer", <i>N. Engl. J Med</i> (2002) 347:1999-2009	
	BI	FERNANDEZ M. D., et al. "Quantitative oestrogen and progesterone receptor values in primary breast cancer and predictability of response to endocrine therapy", <i>Clin Oncol</i> (1983) 9:245-50	
	BJ	FERNÓ, M., et al. "Results of two or five years of adjuvant tamoxifen correlated to steroid receptor and S-phase levels", <i>Breast Cancer Res Treat</i> (2000) 59:69-76	
	BK	NARDELLI, G.B., et al. "Estrogen and progesterone receptors status in the prediction of response of breast cancer to endocrine therapy (preliminary report)", <i>Eur J Gynaecol Oncol</i> (1986) 7:151-8	
WS	BL	OSBORNE, C.K., et al. "The value of estrogen and progesterone receptors in the treatment of breast cancer", <i>Cancer</i> (1980) 46:2884-8	
	BM		

Examiner Signature	/Walter Schlapkohl/	Date Considered	1/31/2007
--------------------	---------------------	-----------------	-----------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>			Complete if Known		
			Application Number	10/727,100	
			Filing Date	December 2, 2003	
			First Named Inventor	Erlander, Mark G.	
			Art Unit	1634 1636	
			Examiner Name	J.S. Simon Schlapkohl	
Sheet	1	of	2	Attorney Docket Number	022041-001410US

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Document Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
WS	AA	US-2003/0219760	A1	11/27/03	Gordon et al.	
	AB	US-				
	AC	US-				
	AD	US-				
	AE	US-				
	AF	US-				
	AG	US-				
	AH	US-				
	AI	US-				
	AJ	US-				
	AK	US-				
	AL	US-				
	AM	US-				
	AN	US-				
	AO	US-				
	AP	US-				
	AQ	US-				
	AR	US-				

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³	Number ⁴	Kind Code ⁵ (if known)				
	AS							<input type="checkbox"/>
	AT							<input type="checkbox"/>
	AU							<input type="checkbox"/>
	AV							<input type="checkbox"/>
	AW							<input type="checkbox"/>

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete If Known	
				Application Number	10/727,100
				Filing Date	December 2, 2003
				First Named Inventor	Erlander, Mark G.
				Art Unit	1684 1636
Examiner Name	J.S. Sitton Schlapkohl				
Sheet	2	of	2	Attorney Docket Number	022041-001410US

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
WS	BA	HOWELL, Sacha J., et al. "The use of selective estrogen receptor modulators and selective estrogen receptor down-regulators in breast cancer", <i>Best Practice & Research Clinical Endocrinology & Metabolism</i> (2004) 18(1):47-66	<input type="checkbox"/>	
	BB	FABIAN, Carol J., et al. "Short-Term Breast Cancer Prediction by Random Periareolar Fine-Needle Aspiration Cytology and the Gail Risk Model", <i>Journal of the National Cancer Institute</i> (2000) 92(15):1217-1227	<input type="checkbox"/>	
	BC	TAN-CHIU, Elizabeth, et al. "Effects of Tamoxifen on Benign Breast Disease in Women at High Risk for Breast Cancer", <i>Journal of the National Cancer Institute</i> (2003) 95(4):302-307	<input type="checkbox"/>	
	BD	HALL, Julie M., et al. "The Multifaceted Mechanisms of Estradiol and Estrogen Receptor Signaling", <i>The Journal of Biological Chemistry</i> (2001) 276(40):36869-36872	<input type="checkbox"/>	
	BE	LEVENSON, Anait S., et al. "Gene Expression Profiles with Activation of the Estrogen Receptor α -Selective Estrogen Receptor Modulator Complex in Breast Cancer Cells Expressing Wild-Type Estrogen Receptor", <i>Cancer Research</i> (2002) 62:4419-4426	<input type="checkbox"/>	
	BF	JORDAN, V. Craig, et al. "Introducing a new section to <i>Breast Cancer Research: Endocrinology and hormone therapy</i> ", <i>Breast Cancer Research</i> (2003) 5:281-283	<input type="checkbox"/>	
	BG	DAUVOIS, Sophie, et al. "Antiestrogen ICI 164,384 reduces cellular estrogen receptor content by increasing its turnover", <i>Proc. Natl. Acad. Sci.</i> (1992) 89:4037-4041	<input type="checkbox"/>	
WS	BH	WILLSON, T.M., et al. "Dissection of the Molecular Mechanism of Action of GW5638, a Novel Estrogen Receptor Ligand, Provides Insights into the Role of Estrogen Receptor in Bone", <i>Endocrinology</i> (1997) 138(9):3901-3911	<input type="checkbox"/>	
	BI	WIJAYARATNE, Ashini L., et al. "Comparative Analyses of Mechanistic Differences Among Antiestrogens", <i>Endocrinology</i> (1999) 140(12):5828-5840	<input type="checkbox"/>	
	BJ	DUTERTRE, Martin, et al. "Molecular Mechanisms of Selective Estrogen Receptor Modulator (SERM) Action", <i>The Journal of Pharmacology and Experimental Therapeutics</i> (2000) 295(2):431-437	<input type="checkbox"/>	
	BK		<input type="checkbox"/>	

Examiner Signature	/Walter Schlapkohl/	Date Considered	1/31/2007
--------------------	---------------------	-----------------	-----------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.